Surgery Partners, Inc. (NASDAQ:SGRY) shares tumbled more than 11% in premarket trading Monday after the company cut its full-year 2025 outlook and reported third-quarter results that fell short of analyst expectations.

The short-stay surgical facility operator posted adjusted earnings of $0.13 per share, missing the consensus estimate of $0.21. Revenue came in at $821.5 million, slightly below projections of $821.86 million, though it still marked a 6.6% year-over-year increase. Same-facility revenue grew 6.3% compared to the prior year.

Surgery Partners sharply revised its 2025 full-year guidance, now forecasting revenue between $3.275 billion and $3.30 billion, down from the analyst consensus of $3.353 billion. The company expects adjusted EBITDA in the range of $535 million to $540 million.

“Considering that volume and payor mix trends were softer than anticipated, coupled with this year’s delayed cadence of capital deployment activities, we have revised our full-year guidance to reflect a prudent approach to the fourth quarter,” said Dave Doherty, Chief Financial Officer.

Despite the weaker guidance, CEO Eric Evans emphasized that the company continues to make operational progress:
“We are proud to report another quarter of solid execution, with revenue and Adjusted EBITDA growth reflecting continued progress in line with our long-term growth algorithm. The continued strength in orthopedic procedures underpinning our topline growth reinforces our leading positioning within the industry.”

For the quarter, Surgery Partners reported a net loss of $22.7 million, while adjusted EBITDA increased 6.1% to $136.4 million, representing a margin of 16.6%, down slightly from 16.7% a year earlier.

The company ended the quarter with $203.4 million in cash and cash equivalents and $405.9 million in available borrowing capacity under its revolving credit facility, maintaining financial flexibility despite near-term challenges.

Surgery Partners stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.